Bridgeway Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Bridgeway Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Sell	25,000 -25,000	-50%	-$244K	0.01%	957
2026 Q1	$466K	Hold	50,000	–	–	0.01%	834
2025 Q4	$375K	Hold	50,000	–	–	0.01%	879
2025 Q3	$435K	Buy	50,000 +25,000	+100%	+$149K	0.01%	830
2025 Q2	$92.8K	Buy	25,000 +12,516	+100%	+$44K	﹤0.01%	1082
2025 Q1	$40.3K	Buy	+12,484	New	+$58.8K	﹤0.01%	1132
2024 Q1	–	Sell	-17,400	Closed	-$353K	–	1332
2023 Q4	$353K	Sell	17,400 -10,000	-36%	-$132K	0.01%	1030
2023 Q3	$349K	Hold	27,400	–	–	0.01%	977
2023 Q2	$495K	Hold	27,400	–	–	0.01%	903
2023 Q1	$471K	Sell	27,400 -15,000	-35%	-$292K	0.01%	906
2022 Q4	$942K	Sell	42,400 -15,000	-26%	-$232K	0.02%	744
2022 Q3	$461K	Buy	+57,400	New	+$520K	0.01%	912

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Bridgeway Capital Management's FDMT Position: Q2 2026 in Review

Bridgeway Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 50% in Q2 2026, selling an estimated $244K and leaving 25,000 shares worth $333K. The position accounts for 0.01% of the portfolio, ranked #957.

Bridgeway Capital Management first reported a position in FDMT in Q3 2022 and has held it in 12 quarters since. The position peaked at $942K in Q4 2022. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Bridgeway Capital Management held 25,000 shares of 4D Molecular Therapeutics worth $333K as of Q2 2026.
Bridgeway Capital Management sold 25,000 4D Molecular Therapeutics shares in Q2 2026, an estimated $244K.
4D Molecular Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #957 holding.
Bridgeway Capital Management first reported a position in 4D Molecular Therapeutics in Q3 2022 and has held it in 12 quarters since.
Bridgeway Capital Management's 4D Molecular Therapeutics position peaked at $942K in Q4 2022.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.